REGRANEX

LOE Approaching

becaplermin

BLATOPICALGEL
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3

Clinical Trials (3)

NCT01235260N/ACompleted

Becaplermin Use and Cancer Risk in a Patient Population of U.S. Veterans With Diabetes

Started Mar 2010
Diabetes MellitusFoot UlcerDiabetic Foot+1 more
NCT00034788Phase 3Terminated

A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

Started Dec 2000
84 enrolled
Foot UlcerDiabetic FootSkin Ulcer+1 more
NCT00740922N/ACompleted

Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers

Started Jul 1999
563 enrolled
Platelet-Derived Growth FactorDiabetic FootNeoplasms
Data Sources
  • Drug label: DailyMed / FDA
  • Clinical trials: ClinicalTrials.gov
  • Patent data: FDA Orange Book
  • Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.